MedTrace Logo

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

NCT04136535 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2025-07-22

No results posted yet for this study

Summary

Evaluate the efficacy and safety of Anlotinib Hydrochloride in combination with Pemetrexed and Carboplatin versus Pemetrexed and Carboplatin for advanced or locally-advanced Osimertinib-resistant non-squamous non-small cell lung cancer.

Conditions

  • NSCLC Stage IV

Interventions

DRUG

Pemetrexed

Pemetrexed，500mg/m²，ivgtt ，d1，q3w

DRUG

Carboplatin

Carboplatin，AUC 5.0，ivgtt，d1，q3w，

DRUG

Anlotinib

Anlotinib ，12 mg，po，qd，d1-14，q3w；

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • chang j hua, PD · PI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04136535 on ClinicalTrials.gov